RxDoctor Payments Data

James Beegan, MD

Physical Medicine & Rehabilitation · Centerville, OHNPI 1508831603

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 613 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among physical medicine & rehabilitation clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,639in general payments, 2019–2025

Across 613 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$688
  • Amgen$659
  • Novartis$549
  • Lilly USA, LLC$527
  • SK Life Science, Inc.$480
  • plus $6K from 54 others
$85,556in research payments, 2019–2025

Across 31 payments — averaging $2759.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$73K
  • Ipsen Pharma SAS$12K

What the payments were for

  • Speaking & faculty fees$691%
  • Food & beverage$10,57099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)107$1,765
UCB, Inc.42$688
Amgen45$659
Novartis41$549
Lilly USA, LLC42$527
SK Life Science, Inc.22$480
AstraZeneca(2 entities)22$424
Biogen20$402
Neurocrine Biosciences, Inc.17$358
Acorda Therapeutics, Inc21$348
Lundbeck LLC18$345
Acadia Pharmaceuticals Inc17$333
EMD Serono, Inc.16$298
Pfizer13$233
Genentech USA, Inc.9$182
Amneal Pharmaceuticals LLC9$167
Argenx US, Inc.7$162
Jazz Pharmaceuticals Inc.8$161
Biohaven Pharmaceutical Holding Company Ltd.10$147
Neurelis, Inc.8$142
Ipsen Biopharmaceuticals, Inc9$131
Takeda Pharmaceuticals U.S.A., Inc.5$129
Eisai Inc.6$125
MDD US Operations, LLC7$123
Merz Pharmaceuticals, LLC6$123
Biohaven Pharmaceuticals, Inc.5$110
Alnylam Pharmaceuticals Inc.5$109
Insightec,inc2$106
GE HealthCare3$95
Sunovion Pharmaceuticals Inc.5$88
Axsome Therapeutics, Inc.4$83
Octapharma USA, Inc.5$81
Supernus Pharmaceuticals, Inc.4$71
Harmony Biosciences LLC3$69
Sumitomo Pharma America, Inc.3$62
Greenwich Biosciences, Inc.4$61
CSL Behring4$57
Avanir Pharmaceuticals, Inc.4$55
Adamas Pharmaceuticals, Inc.4$55
Grifols USA, LLC3$51
Johnson & Johnson2$45
TG Therapeutics, Inc.2$38
Aprecia Pharmaceuticals, LLC2$34
Sanofi2$29
Teva Pharmaceuticals USA, Inc.2$28
Revance Therapeutics, Inc.1$26
Catalyst Pharmaceuticals, Inc.1$25
Philips North America LLC1$22
Scilex Pharmaceuticals Inc.1$21
Otsuka America Pharmaceutical, Inc.1$21
Banner Life Sciences, LLC1$20
Merz North America, Inc.1$18
Upsher-smith Laboratories LLC1$18
Amylyx Pharmaceuticals, Inc.1$18
Cala Health, Inc.1$17
Akcea Therapeutics, Inc.1$16
Aquestive Therapeutics, Inc.1$16
Kyowa Kirin, Inc.1$15
Currax Pharmaceuticals LLC1$15
Alfasigma USA, Inc.1$13

How this compares

$10,639 in reported general payments places this provider in the 95th percentile of 332 physical medicine & rehabilitation providers in Ohio.

See all physical medicine & rehabilitation providers in Ohio

Medicare billing

Part B allowed, 2024
$384,048
Medicare patients
312
Services billed
38,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina37$88,032
Gabapentin35$1,557
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$830
Tizanidine Hcl17$640
Amitriptyline Hcl24$336
Tramadol Hcl11$212
Diazepam14$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$1,765$88,03237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 332 physical medicine & rehabilitation providers in Ohio.

Other physical medicine & rehabilitation in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →